alantir Q3 revenue surged 63% YoY on booming defense orders; full-year guidance raised.
Palantir reported Q3 revenue of $1.18 billion, a surge of 63% year-over-year, beating analysts’ expectations of $1.09 billion. This marks the 21st consecutive quarter that PLTR has topped Wall Street estimates. The company also significantly raised its full-year revenue guidance to $4.40 billion, up from the previous range of $4.14–$4.15 billion—its third upward revision this year.
Palantir is experiencing unprecedented growth in its U.S. commercial segment, with revenue expected to exceed $1.433 billion, representing a 104% increase. However, U.S. government sales showed a slight sequential slowdown, rising 52% year-over-year (compared to 53% in Q2). After hours, Palantir’s stock initially jumped 7% before quickly pulling back.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
RNA therapy company Adarx Pharmaceuticals (ADRX.US) plans to raise up to $372 million in a U.S. IPO; pharmaceutical giant AbbVie (ABBV.US) has agreed to invest up to $100 million
RNA therapy company Adarx Pharmaceuticals, which is in the late stage of clinical development, plans to raise up to $371.9 million through its initial public offering (IPO) in the United States.
Ledger CTO urges crypto holders to update iPhones after DarkSword exploit revealed
Crypto ICOs Left in Limbo After CLARITY Act Fails in Senate